3,916 results match your criteria Borderline Ovarian Cancer


Low-grade serous epithelial ovarian cancer: a comprehensive review and update for radiologists.

Insights Imaging 2021 May 11;12(1):60. Epub 2021 May 11.

Department of Radiology, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal.

Low-grade serous carcinoma (LGSC) is an infrequent subtype of ovarian cancer, corresponding to 5% of epithelial neoplasms. This subtype of ovarian carcinoma characteristically has molecular features, pathogenesis, clinical behaviour, sensitivity to chemotherapy, and prognosis distinct to high-grade serous carcinoma (HGSC). Knowing the difference between LGSC and other ovarian serous tumours is vital to guide clinical management, which currently is only possible histologically. Read More

View Article and Full-Text PDF

Ovarian mucinous and seromucinous neoplasms: problematic aspects and modern diagnostic approach.

Histopathology 2021 May 7. Epub 2021 May 7.

Department of Pathology, Belfast Health and Social Care Trust, Belfast, United Kingdom.

The morphological spectrum of primary ovarian mucinous and seromucinous tumours is broad and presents an array of diagnostic challenges, many unique to these tumour types. This reflects the heterogeneous nature of these lesions, their varied histogenesis and evolving classification systems over recent decades, with further modification to the seromucinous category incorporated in the recently published 5 edition of the WHO Classification of Female Genital Tumours. In this review we provide an update on the classification of these neoplasms and discuss their histogenesis and diverse morphology, focusing on areas which are diagnostically problematic. Read More

View Article and Full-Text PDF

Anaplastic carcinoma showing rhabdoid features combined with ovarian mucinous borderline cystadenoma: a case report and literature review.

J Int Med Res 2021 May;49(5):3000605211013159

Department of Gynecology, Sun Yat-sen University First Affiliated Hospital, Guangzhou, China.

Anaplastic carcinoma in an ovarian tumor (ACOT) is rare. There have been a few controversial cases illustrating the clinical characteristics and prognostic factors of ACOT, which are not well known. A 60-year-old Chinese woman presented with a large pelvic tumor. Read More

View Article and Full-Text PDF

Retrospective Analysis of Factors Affecting Recurrence in Borderline Ovarian Tumors.

South Asian J Cancer 2020 Jul 19;9(3):168-173. Epub 2021 Mar 19.

Department of Biostatistics, Amrita Institute of Medical Sciences, Amrita University, Kochi, Kerala, India.

 Borderline ovarian tumors (BOTs) are an intermediate form of neoplasia, between benign and malignant. The aim of this retrospective analysis is to evaluate the clinicopathological characteristic profile of BOTs and to determine the predictors of recurrence in BOTs.  A retrospective review of all patients diagnosed, treated, and followed up for BOTs between 2010 and 2017 at Amrita Institute of Medical Sciences, Kerala, India, was conducted. Read More

View Article and Full-Text PDF

Dysregulated Immunological Functionome and Dysfunctional Metabolic Pathway Recognized for the Pathogenesis of Borderline Ovarian Tumors by Integrative Polygenic Analytics.

Int J Mol Sci 2021 Apr 15;22(8). Epub 2021 Apr 15.

Department of Obstetrics and Gynecology, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan.

The pathogenesis and molecular mechanisms of ovarian low malignant potential (LMP) tumors or borderline ovarian tumors (BOTs) have not been fully elucidated to date. Surgery remains the cornerstone of treatment for this disease, and diagnosis is mainly made by histopathology to date. However, there is no integrated analysis investigating the tumorigenesis of BOTs with open experimental data. Read More

View Article and Full-Text PDF

The role of inflammation biomarkers in differential diagnosis of pelvic tumours of ovarian origin: a single-centre observational study.

Contemp Oncol (Pozn) 2021 15;25(1):7-11. Epub 2021 Apr 15.

Department of Gynaecological Oncology, Metaxa Memorial Cancer Hospital, Piraeus, Greece.

Aim Of The Study: Our aim was to analyse the feasibility of white blood cell and platelet counts along with their ratios as a prognostic factor in patients who underwent surgery for ovarian mass.

Material And Methods: We retrospectively studied the patients admitted in the Department of Gynaecology due to adnexal mass. The potential association of the neutrophil-to-lymphocyte-ratio (NLR), neutrophil-to-monocyte (NMR), platelet-to-lymphocyte (PLR), lymphocyte-to-monocyte (LMR), monocyte-to-platelet, and malignancy was evaluated. Read More

View Article and Full-Text PDF

Status of Surgical Management of Borderline Ovarian Tumors in France: are Recommendations Being Followed? Multicentric French Study by the FRANCOGYN Group.

Ann Surg Oncol 2021 Apr 26. Epub 2021 Apr 26.

Department of Gynecologic Surgery, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.

Background: Borderline ovarian tumors (BOTs) are tumors with a favorable prognosis but whose management by consensus is essential to limit the risk of invasive recurrence. This study aimed to conduct an inventory of surgical practices for BOT in France and to evaluate the conformity of the treatment according to the current French guidelines.

Methods: This retrospective, multicenter cohort study included nine referral centers of France between January 2001 and December 2018. Read More

View Article and Full-Text PDF

Oncologic and reproductive outcomes of borderline ovarian tumors in Indian population.

Gynecol Oncol Rep 2021 May 23;36:100756. Epub 2021 Mar 23.

Department of Medical Oncology, Dr. B.R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India.

Borderline ovarian tumor (BOT) is characterized by atypical epithelial proliferation without stromal invasion and majority are diagnosed at early stages and in women of reproductive age group. A retrospective review of medical records of patients diagnosed with BOT and on regular follow up at All India Institute of Medical Sciences New Delhi, during a five-year study period from March 2014 to March 2019 was performed. Surgical treatment was classified as radical, fertility sparing surgery (FSS) or cystectomy. Read More

View Article and Full-Text PDF

Salpingo-oophorectomy versus cystectomy in patients with borderline ovarian tumors: a systemic review and meta-analysis on postoperative recurrence and fertility.

Authors:
Peng Wang Lei Fang

World J Surg Oncol 2021 Apr 21;19(1):132. Epub 2021 Apr 21.

Beijing Obstertrics and Gynecology Hospital, Capital Medical University, No. 251 Yao Jiayuan Road, Chaoyang District, Beijing, 100026, China.

Background: To compare the postoperative recurrence and fertility in patients with borderline ovarian tumors (BOTs) who underwent different surgical procedures: salpingo-oophorectomy versus cystectomy.

Methods: Potentially relevant literature from inception to Nov. 06, 2020, were retrieved in databases including Cochrane Library, EMBASE (Ovid), and MEDLINE (Pubmed). Read More

View Article and Full-Text PDF

CA125 test result, test-to-diagnosis interval, and stage in ovarian cancer at diagnosis: a retrospective cohort study using electronic health records.

Br J Gen Pract 2021 Feb 3. Epub 2021 Feb 3.

The Primary Care Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge.

Background: In the UK, the cancer antigen 125 (CA125) test is recommended as a first-line investigation in women with symptoms of possible ovarian cancer.

Aim: To compare time between initial primary care CA125 test and diagnosis, tumour morphology, and stage in women with normal (<35 U/ml) and abnormal (≥35 U/ml) CA125 levels prior to ovarian cancer diagnosis.

Design And Setting: Retrospective cohort study using English primary care and cancer registry data. Read More

View Article and Full-Text PDF
February 2021

[Current WHO classification of the female genitals : Many new things, but also some old].

Pathologe 2021 May 6;42(3):259-269. Epub 2021 Apr 6.

Arbeitsgruppe Mamma‑, Gynäko- & Perinatalpathologie, Institut für Pathologie, Universitätsklinikum Leipzig AöR, Leipzig, Deutschland.

The new WHO classification of tumors of the female genitalia entails some changes, especially those of prognostic and therapeutic relevance: there is a return to the term borderline tumor. Implants are again subdivided into noninvasive implants of the epithelial or desmoplastic type as before. Invasive extraovarian implants are classified as low-grade serous carcinoma (LGSC). Read More

View Article and Full-Text PDF

Fertility preservation in women with malignant and borderline ovarian tumors: Experience of the French ESGO-certified center and pregnancy-associated cancer network (CALG).

Gynecol Oncol 2021 Mar 31. Epub 2021 Mar 31.

Department of Gynaecology, Obstetrics and Reproductive Medicine, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Sorbonne University, University Institute of Cancer, Paris, France; Department of Gynaecology and Obstetrics, Pregnancy associated cancer network (CALG), Paris, France; INSERM UMR S 938, Biology and therapy of cancer, St Antoine research center, Paris, France.

Objective: To describe strategy and results of fertility preservation (FP) in patients with malignant and borderline ovarian tumors.

Methods: Consecutive cohort study of 43 women with malignant or borderline ovarian tumors who underwent FP between February 2013 and July 2019. The study was conducted in national expert center in Tenon University Hospital, Sorbonne University: French ESGO-certified ovarian cancer center and pregnancy-associated cancer network (CALG). Read More

View Article and Full-Text PDF

Recurrence characteristics and clinicopathological results of borderline ovarian tumors.

BMC Womens Health 2021 Mar 31;21(1):134. Epub 2021 Mar 31.

Department of Gynecology, First Hospital of Shanxi Medical University, NO.85 South Jiefang Road, Yingze District, Taiyuan, 030001, China.

Background: This study aimed to investigate the clinical and pathological characteristics, and the recurrence and prognostic factors of borderline ovarian tumors (BOTs).

Methods: The data of 286 patients admitted to hospital and followed up for more than ten months were analyzed retrospectively to study the clinicopathological characteristics and related factors of recurrence.

Results: The median age of the patients was 42. Read More

View Article and Full-Text PDF

The impact of the COVID-19 coronavirus pandemic on the surgical management of gynecological cancers: Analysis of the multicenter database of the French SCGP and the FRANCOGYN group.

J Gynecol Obstet Hum Reprod 2021 Mar 28;50(8):102133. Epub 2021 Mar 28.

Departement of Obstetrics and Gynecology, Angers University Hospital, Angers, France; CESP-INSERM, U1018, Team 7, Reproductive and sexual health, Paris-Sud University, 94276 Villejuif, France. Electronic address:

Introduction: The coronavirus SARS-CoV-2 (COVID-19) pandemic has put tremendous pressure on the French healthcare system. Almost all hospital departments have had to profoundly modify their activity to cope with the crisis. In this context, the surgical management of cancers has been a topic of debate as care strategies were tailored to avoid any delay in treatment that could be detrimental to patient wellbeing while being careful not to overload intensive care units. Read More

View Article and Full-Text PDF

Prominent Papillary Growth Pattern and Severe Nuclear Pleomorphism Induced by Neoadjuvant Chemotherapy in Ovarian Mucinous Carcinoma: Potential for Misdiagnosis as High-grade Serous Carcinoma.

Anticancer Res 2021 Mar;41(3):1579-1586

Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

Background/aim: Histological changes induced by neoadjuvant chemotherapy (NAC) have rarely been reported in histological subtypes other than ovarian high-grade serous carcinoma (HGSC).

Case Report: We report a 49-year-old woman whose tumors in interval debulking surgery (IDS) specimen exhibited prominent papillary growth pattern and severe nuclear pleomorphism due to NAC. In the initial microscopic examination, ovarian HGSC was the most likely candidate; however, immunostaining results were not compatible with HGSC. Read More

View Article and Full-Text PDF

Development of Aptamer-Based Molecular Tools for Rapid Intraoperative Diagnosis and Imaging of Serous Ovarian Cancer.

ACS Appl Mater Interfaces 2021 Apr 31;13(14):16118-16126. Epub 2021 Mar 31.

State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University, Tianjin 300350, P. R. China.

Diagnosis and treatment of ovarian cancer are based on intraoperative pathology and debulking surgery. The development of a novel molecular tool is significant for rapid intraoperative pathologic diagnosis, which instructs the decision-making on excision surgery and effective chemotherapy. In this work, we represent a DNA aptamer named mApoc46, which is generated from cell-SELEX by targeting patient-derived primary serous ovarian cancer (pSOC) cells. Read More

View Article and Full-Text PDF

WT1 Positive Ovarian Endometrioid Tumors: Observations From Consult Cases and Strategies for Distinguishing From Serous Neoplasms.

Int J Gynecol Pathol 2021 Mar 29. Epub 2021 Mar 29.

Department of Pathology, Belfast Health and Social Care Trust, Belfast, Northern Ireland, UK (S.R., W.G.M.).

Ovarian endometrioid carcinoma, more than any other type of ovarian epithelial malignancy, demonstrates a varied morphology which can cause problems in diagnosis. In tubo-ovarian tumor pathology, WT1 is a commonly used marker as it is consistently expressed in low-grade and high-grade serous carcinomas and is often considered a specific marker of a serous phenotype. However, ovarian endometrioid neoplasms may also express WT1 which may contribute to misdiagnosis. Read More

View Article and Full-Text PDF

Fertility-sparing treatment in advanced-stage serous borderline ovarian tumors. An analysis from the MITO14 study database.

Gynecol Oncol 2021 Mar 26. Epub 2021 Mar 26.

Department of Gynecologic Oncology, Istituto Nazionale Tumori, IRCSS, "Fondazione G. Pascale", Naples, Italy. Electronic address:

Objectives: To evaluate oncological and reproductive outcomes of women undergoing fertility-sparing surgery (FSS) for stage II-III serous borderline ovarian tumors (BOTs).

Methods: A multi-institutional retrospective study was conducted within the MITO Group.

Results: A total of 91 patients were recruited. Read More

View Article and Full-Text PDF

Clinical value of N-acetyl mucinous compounds and lipid peaks in differentiating benign and malignant ovarian mucinous tumors by MR spectroscopy.

Clin Imaging 2021 Mar 22;78:127-135. Epub 2021 Mar 22.

Department of Radiology, Tokushima University, 3-18-15, Kuramoto-cho, Tokushima zip: 7708503, Japan. Electronic address:

Purpose: To retrospectively evaluate the clinical significance of the peaks of N-acetyl mucinous compounds (NAMC) at 2 ppm and lipid at 1.3 ppm in in-vivo proton magnetic resonance (MR) spectroscopy for distinguishing benign and malignant mucinous tumors in patients with ovarian masses.

Methods: MR spectroscopy was performed in patients with pathologically diagnosed mucinous ovarian tumors at 3 T MRI system. Read More

View Article and Full-Text PDF

Mutational spectrum in clinically aggressive low-grade serous carcinoma/serous borderline tumors of the ovary-Clinical significance of BRCA2 gene variants in genomically stable tumors.

Gynecol Oncol 2021 Mar 24. Epub 2021 Mar 24.

Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA; Department of Pathology, St. Michael's Hospital, Toronto, Ontario, Canada. Electronic address:

Objective: The mutational spectra of low-grade serous carcinomas (LGSCs) and serous borderline tumors (SBTs) of the ovary are poorly characterized. We present 17 cases of advanced or recurrent LGSC/SBT patients who underwent molecular profiling.

Methods: Thirteen LGSCs and four SBTs underwent targeted gene panel testing by massively parallel sequencing. Read More

View Article and Full-Text PDF

Long-Term Risk of Ovarian Cancer and Borderline Tumors After Assisted Reproductive Technology.

J Natl Cancer Inst 2020 Nov 17. Epub 2020 Nov 17.

Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands.

Background: Long-term effects of assisted reproductive technology (ART) on ovarian tumor risk are unknown.

Methods: This nationwide cohort study comprises 30 625 women who received ovarian stimulation for ART in 1983-2000 and 9988 subfertile women not treated with ART. Incident invasive and borderline ovarian tumors were ascertained through linkage with the Netherlands Cancer Registry and the Dutch Pathology Registry until July 2018. Read More

View Article and Full-Text PDF
November 2020

Predicting Malignancy in Adnexal Masses by the International Ovarian Tumor Analysis-Simple Rules.

J Midlife Health 2020 Oct-Dec;11(4):217-223. Epub 2021 Jan 21.

Department of Obstetrics and Gynecology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.

Background: Accurate prediction of adnexal tumors preoperatively is critical for optimal management of ovarian cancers. The International Ovarian Tumor Analysis Algorithms (IOTA) is a newer tool to characterize adnexal masses as benign or malignant.

Objective: This study is aimed to predict malignancy in adnexal masses and differentiates benign from malignant, applying the sonography features of simple rules given by IOTA. Read More

View Article and Full-Text PDF
January 2021

Concurrent gynecologic surgery and panniculectomy in morbidly obese women with gynecologic cancer, a single-center experience.

Arch Gynecol Obstet 2021 Mar 19. Epub 2021 Mar 19.

Gynecologic Oncology Department, Metaxa Memorial Cancer Hospital, 51, Botassi Str., 18537, Piraeus, Greece.

Purpose: As the prevalence of obesity has been rising during the past decades worldwide and especially in Greece, surgeons have faced significant challenges concerning the treatment of morbidly obese women with gynecologic cancer. Panniculectomy is a safe procedure that offers better visualization of pelvic anatomy and prevention of major complications in these women.

Methods: Aim of this study is to describe a single-center experience of surgical treatment of morbidly obese women with gynecologic cancer and concurrent panniculectomy. Read More

View Article and Full-Text PDF

Ovarian seromucinous tumors: clinicopathological features of 10 cases with a detailed review of the literature.

J Ovarian Res 2021 Mar 18;14(1):47. Epub 2021 Mar 18.

Department of Pathology and Laboratory Medicine, Aga Khan University Hospital, Karachi, Pakistan.

Background: The 2014 WHO Classification of ovarian neoplasms introduced a new entity of seromucinous tumors associated with endometriosis. These tumors encompassed a spectrum from benign to malignant and included seromucinous cystadenoma/ cystadenofibroma, seromucinous borderline tumor/atypical proliferative seromucinous tumor and seromucinous carcinoma. However, the 2020 WHO Classification of Female Genital Tumours removed seromucinous carcinomas as a distinct entity and recategorized them as Endometrioid carcinomas with mucinous differentiation. Read More

View Article and Full-Text PDF

The poor prognosis of sarcomatoid carcinoma arising from low grade serous ovarian cancer: A case report and review of the literature.

Gynecol Oncol Rep 2021 May 23;36:100735. Epub 2021 Feb 23.

Division of Gynecologic Oncology, The Ohio State University Wexner Medical Center, M210 Starling Loving Hall, 320 W 10 Avenue, Columbus, OH 43210, United States.

Sarcomatoid or anaplastic carcinomas arising within epithelial ovarian neoplasms are rare, particularly within serous tumors of the ovary, and carry a poor prognosis. Here we present the case of a patient initially diagnosed with low grade serous ovarian carcinoma arising within a serous borderline tumor (atypical proliferative serous tumor). She underwent rapid progression of disease and was found to have anaplastic/sarcomatoid carcinoma on biopsy of recurrence. Read More

View Article and Full-Text PDF

The usefulness of intraoperative consultation for the diagnosis of borderline ovarian tumors.

Ann Transl Med 2021 Feb;9(3):261

Surgical Oncology, National Cancer Institute, Mexico City, Mexico.

Background: Borderline ovarian tumors (BTs) must be recognized during the surgery by intraoperative consultation (IOC) to guide surgical treatment; however, this diagnosis can be imprecise. Therefore, this study aimed to evaluate the diagnostic accuracy of IOC for the diagnosis of BT.

Methods: A retrospective cohort study was carried out including all women diagnosed with a pelvic tumor consecutively surgically treated from 2005 to 2015 with IOC. Read More

View Article and Full-Text PDF
February 2021

Serum Free Amino Acid Profiling in Differential Diagnosis of Ovarian Tumors-A Comparative Study with Review of the Literature.

Int J Environ Res Public Health 2021 02 23;18(4). Epub 2021 Feb 23.

Faculty of Health Sciences, Calisia University, 13 Kaszubska Street, 62-800 Kalisz, Poland.

Proper preoperative ovarian cancer (OC) diagnosis remains challenging. Serum free amino acid (SFAA) profiles were investigated to identify potential novel biomarkers of OC and assess their performance in ovarian tumor differential diagnosis. Serum samples were divided based on the histopathological result: epithelial OC ( = 38), borderline ovarian tumors ( = 6), and benign ovarian tumors (BOTs) ( = 62). Read More

View Article and Full-Text PDF
February 2021

Characterization and clinical significance of the CADM1/HER2/STAT3 axis in serous ovarian tumors.

Medicine (Baltimore) 2021 Feb;100(8):e23777

Department of Obstetrics and Gynecology, the Second Affiliated Hospital of University of South China, Hunan.

Abstract: The subtypes of serous ovarian tumors (SOTs), including benign serous cystadenoma, serous borderline tumor (SBT), low-grade serous ovarian carcinoma (LGSC), and high-grade serous ovarian carcinoma (HGSC), remain poorly understood. Herein, we aimed to characterize the cell adhesion molecule 1 (CADM1)/signal transducer and activator of transcription 3 (STAT3)/human epidermal growth factor receptor 2 (HER2) axis and identify its clinical significance in patients with serous cystadenoma, SBT, LGSC, and HGSC.The immunohistochemical expression of CADM1, HER2, and STAT3 was assessed in 180 SOT specimens, and its association with clinical data was determined. Read More

View Article and Full-Text PDF
February 2021

Are CT and MRI useful tools to distinguish between micropapillary type and typical type of ovarian serous borderline tumors?

Abdom Radiol (NY) 2021 Mar 3. Epub 2021 Mar 3.

Department of Radiology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, No. 519 Kunzhou Road, Xishan District, Kunming, 650118, Yunnan, People's Republic of China.

Purpose: To investigate the computed tomography (CT) and magnetic resonance imaging (MRI) characteristics of ovarian serous borderline tumors (SBTs), and evaluate whether CT and MRI can be used to distinguish micropapillary from typical subtypes.

Materials And Methods: We retrospectively reviewed the clinical features and CT and MR imaging findings of 47 patients with SBTs encountered at our institute from September 2013 to December 2019. 30 patients with 58 histologically proven typical SBT and 17 patients with 26 micropapillary SBT were reviewed. Read More

View Article and Full-Text PDF